IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-56482-w.html
   My bibliography  Save this article

The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial

Author

Listed:
  • Matthew Stephen Block

    (Mayo Clinic Cancer Center)

  • James Hugo Armstrong Clubb

    (TILT Biotherapeutics Ltd
    University of Helsinki)

  • Johanna Mäenpää

    (Docrates Cancer Center
    Faculty of Medicine and Medical Technology)

  • Santeri Pakola

    (University of Helsinki)

  • Dafne Carolina Alves Quixabeira

    (TILT Biotherapeutics Ltd
    University of Helsinki)

  • Tatiana Kudling

    (TILT Biotherapeutics Ltd
    University of Helsinki)

  • Elise Jirovec

    (TILT Biotherapeutics Ltd
    University of Helsinki)

  • Lyna Haybout

    (TILT Biotherapeutics Ltd
    University of Helsinki)

  • Mirte Heijden

    (University of Helsinki)

  • Sanae Zahraoui

    (TILT Biotherapeutics Ltd)

  • Susanna Grönberg-Vähä-Koskela

    (University of Helsinki)

  • Sini Raatikainen

    (TILT Biotherapeutics Ltd)

  • Victor Arias

    (University of Helsinki)

  • Saru Basnet

    (University of Helsinki)

  • Nea Ojala

    (University of Helsinki)

  • Teijo Pellinen

    (Institute for Molecular Medicine Finland)

  • Annabrita Hemmes

    (Institute for Molecular Medicine Finland)

  • Katja Välimäki

    (Institute for Molecular Medicine Finland)

  • Annukka Pasanen

    (University of Helsinki and Helsinki University Hospital)

  • Tuomo Alanko

    (Docrates Cancer Center)

  • Daniel Adamo

    (Mayo Clinic Cancer Center)

  • Susan Ramadan

    (Docrates Cancer Center)

  • Jorma Sormunen

    (Docrates Cancer Center)

  • Juha Kononen

    (Docrates Cancer Center)

  • Julia Wanda Cohen

    (Merck & Co. Inc.)

  • Michael Jon Chisamore

    (Merck & Co. Inc.)

  • John Goldfinch

    (TILT Biotherapeutics Ltd)

  • Suvi Sorsa

    (TILT Biotherapeutics Ltd
    University of Helsinki)

  • Riikka Havunen

    (TILT Biotherapeutics Ltd
    University of Helsinki)

  • Claudia Kistler

    (TILT Biotherapeutics Ltd)

  • Aino Kalervo

    (TILT Biotherapeutics Ltd)

  • Víctor Cervera-Carrascon

    (TILT Biotherapeutics Ltd
    University of Helsinki)

  • João Manuel Santos

    (TILT Biotherapeutics Ltd
    University of Helsinki)

  • Akseli Hemminki

    (TILT Biotherapeutics Ltd
    University of Helsinki
    Helsinki University Hospital)

Abstract

Immune checkpoint inhibitors have demonstrated modest efficacy as a monotherapy in ovarian cancer. Originally developed to improve efficacy of T-cell therapies such as immune checkpoint inhibitors and adoptive cell transfer, TILT-123 (Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) is a serotype chimeric oncolytic adenovirus encoding tumor necrosis factor alpha and interleukin-2. Here we report results from phase 1a of PROTA, a single-arm, multicentre dose escalation trial with TILT-123 and pembrolizumab in female patients with platinum resistant or refractory ovarian cancer (NCT05271318). The primary endpoint was safety. Secondary endpoints included efficacy, tolerability, virus persistence and anti-viral immunity. Patients (n = 15) received intravenous and intraperitoneal and/or intratumoral injections of TILT-123 as well as intravenous pembrolizumab. Treatment was well tolerated, and no dose-limiting toxicities were observed. The most frequent adverse events were fever (40%), fatigue (40%) and nausea (40%). Disease control was achieved in 64% of evaluable patients (9/14). Median progression-free survival and overall survival were 98 and 190 days respectively. Clinical responses were associated with higher serum anti-adenovirus neutralizing antibody titer at baseline and post-treatment. The phase 1b investigating TILT-123, pembrolizumab and PEGylated liposomal doxorubicin in a similar patient population is underway.

Suggested Citation

  • Matthew Stephen Block & James Hugo Armstrong Clubb & Johanna Mäenpää & Santeri Pakola & Dafne Carolina Alves Quixabeira & Tatiana Kudling & Elise Jirovec & Lyna Haybout & Mirte Heijden & Sanae Zahraou, 2025. "The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial," Nature Communications, Nature, vol. 16(1), pages 1-14, December.
  • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-56482-w
    DOI: 10.1038/s41467-025-56482-w
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-56482-w
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-025-56482-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Alexander L. Ling & Isaac H. Solomon & Ana Montalvo Landivar & Hiroshi Nakashima & Jared K. Woods & Andres Santos & Nafisa Masud & Geoffrey Fell & Xiaokui Mo & Ayse S. Yilmaz & James Grant & Abigail Z, 2023. "Clinical trial links oncolytic immunoactivation to survival in glioblastoma," Nature, Nature, vol. 623(7985), pages 157-166, November.
    2. Laura Codarri Deak & Valeria Nicolini & Masao Hashimoto & Maria Karagianni & Petra C. Schwalie & Laura Lauener & Eleni Maria Varypataki & Marine Richard & Esther Bommer & Johannes Sam & Stefanie Jolle, 2022. "PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells," Nature, Nature, vol. 610(7930), pages 161-172, October.
    3. Beth A. Helmink & Sangeetha M. Reddy & Jianjun Gao & Shaojun Zhang & Rafet Basar & Rohit Thakur & Keren Yizhak & Moshe Sade-Feldman & Jorge Blando & Guangchun Han & Vancheswaran Gopalakrishnan & Yuanx, 2020. "B cells and tertiary lymphoid structures promote immunotherapy response," Nature, Nature, vol. 577(7791), pages 549-555, January.
    4. Subir Biswas & Gunjan Mandal & Kyle K. Payne & Carmen M. Anadon & Chandler D. Gatenbee & Ricardo A. Chaurio & Tara Lee Costich & Carlos Moran & Carly M. Harro & Kristen E. Rigolizzo & Jessica A. Mine , 2021. "IgA transcytosis and antigen recognition govern ovarian cancer immunity," Nature, Nature, vol. 591(7850), pages 464-470, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Spencer R. Rosario & Mark D. Long & Shanmuga Chilakapati & Eduardo Cortes Gomez & Sebastiano Battaglia & Prashant K. Singh & Jianmin Wang & Katy Wang & Kristopher Attwood & Suzanne M. Hess & AJ Robert, 2024. "Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    2. Lenka Kasikova & Jana Rakova & Michal Hensler & Tereza Lanickova & Jana Tomankova & Josef Pasulka & Jana Drozenova & Katerina Mojzisova & Anna Fialova & Sarka Vosahlikova & Jan Laco & Ales Ryska & Pav, 2024. "Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    3. Joseph R. Palmeri & Brianna M. Lax & Joshua M. Peters & Lauren Duhamel & Jordan A. Stinson & Luciano Santollani & Emi A. Lutz & William Pinney & Bryan D. Bryson & K. Dane Wittrup, 2024. "CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    4. Jia Wei & Xiaofeng Lu & Qin Liu & Yao Fu & Song Liu & Yang Zhao & Jiawei Zhou & Hui Chen & Meng Wang & Lin Li & Ju Yang & Fangcen Liu & Liming Zheng & Haitao Yin & Yang Yang & Chong Zhou & Ping Zeng &, 2023. "Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    5. Sangeeta Goswami & Jianjun Gao & Sreyashi Basu & Daniel D. Shapiro & Jose A. Karam & Rebecca Slack Tidwell & Kamran Ahrar & Matthew T. Campbell & Yu Shen & Alexandro E. Trevino & Aaron T. Mayer & Alex, 2025. "Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial," Nature Communications, Nature, vol. 16(1), pages 1-13, December.
    6. Marina Baretti & Ludmila Danilova & Jennifer N. Durham & Courtney B. Betts & Leslie Cope & Dimitrios N. Sidiropoulos & Joseph A. Tandurella & Soren Charmsaz & Nicole Gross & Alexei Hernandez & Won Jin, 2024. "Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    7. Nanda Horeweg & Hagma H. Workel & Dominik Loiero & David N. Church & Lisa Vermij & Alicia Léon-Castillo & Ricki T. Krog & Stephanie M. Boer & Remi A. Nout & Melanie E. Powell & Linda R. Mileshkin & He, 2022. "Tertiary lymphoid structures critical for prognosis in endometrial cancer patients," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    8. Julia Paczkowska & Ming Tang & Kyle T. Wright & Li Song & Kelsey Luu & Vignesh Shanmugam & Emma L. Welsh & Jason L. Weirather & Naomi Besson & Harrison Olszewski & Billie A. Porter & Kathleen L. Pfaff, 2024. "Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    9. Soizic Garaud & Marie-Caroline Dieu-Nosjean & Karen Willard-Gallo, 2022. "T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy," Nature Communications, Nature, vol. 13(1), pages 1-4, December.
    10. Liang Zhang & Boxin Zhang & Meng-Jie Zhang & Wenlang Li & Hao Li & Yantian Jiao & Qi-Chao Yang & Shuo Wang & Yuan-Tong Liu & An Song & Hai-Tao Feng & Jianwei Sun & Ryan T. K. Kwok & Jacky W. Y. Lam & , 2025. "Trigger inducible tertiary lymphoid structure formation using covalent organic frameworks for cancer immunotherapy," Nature Communications, Nature, vol. 16(1), pages 1-16, December.
    11. Mattia Rediti & Aranzazu Fernandez-Martinez & David Venet & Françoise Rothé & Katherine A. Hoadley & Joel S. Parker & Baljit Singh & Jordan D. Campbell & Karla V. Ballman & David W. Hillman & Eric P. , 2023. "Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    12. Akshay J. Patel & Zena N. Willsmore & Naeem Khan & Alex Richter & Babu Naidu & Mark T. Drayson & Sophie Papa & Andrew Cope & Sophia N. Karagiannis & Esperanza Perucha & Gary W. Middleton, 2022. "Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    13. Olivia Le Saux & Maude Ardin & Justine Berthet & Sarah Barrin & Morgane Bourhis & Justine Cinier & Yasmine Lounici & Isabelle Treilleux & Pierre-Alexandre Just & Guillaume Bataillon & Aude-Marie Savoy, 2024. "Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    14. Rana Falahat & Anders Berglund & Patricio Perez-Villarroel & Ryan M. Putney & Imene Hamaidi & Sungjune Kim & Shari Pilon-Thomas & Glen N. Barber & James J. Mulé, 2023. "Epigenetic state determines the in vivo efficacy of STING agonist therapy," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    15. Li Yuan & Guo-Dong Jia & Xiao-Fei Lv & Si-Yi Xie & Shan-Shan Guo & Da-Feng Lin & Li-Ting Liu & Dong-Hua Luo & Yi-Fu Li & Shen-Wen Deng & Ling Guo & Mu-Sheng Zeng & Xiu-Yu Cai & Sai-Lan Liu & Xue-Song , 2023. "Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    16. Kateryna Onyshchenko & Ren Luo & Elena Guffart & Simone Gaedicke & Anca-Ligia Grosu & Elke Firat & Gabriele Niedermann, 2023. "Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    17. Yoshito Yamada & Tuan Thanh Nguyen & Daniela Impellizzieri & Katsutaka Mineura & Rintaro Shibuya & Alvaro Gomariz & Martina Haberecker & Jakob Nilsson & César Nombela-Arrieta & Wolfgang Jungraithmayr , 2023. "Biased IL-2 signals induce Foxp3-rich pulmonary lymphoid structures and facilitate long-term lung allograft acceptance in mice," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    18. Jieqiong Liu & Ying Wang & Zhenluan Tian & Ying Lin & Hengyu Li & Zhaowen Zhu & Qiang Liu & Shicheng Su & Yinduo Zeng & Weijuan Jia & Yaping Yang & Shengqiang Xu & Herui Yao & Wen Jiang & Erwei Song, 2022. "Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    19. Kenny K. H. Yu & Sreyashi Basu & Gerard Baquer & Ryuhjin Ahn & Jennifer Gantchev & Sonali Jindal & Michael S. Regan & Zaki Abou-Mrad & Michael C. Prabhu & Marc J. Williams & Alicia D. D’Souza & Seth W, 2025. "Investigative needle core biopsies support multimodal deep-data generation in glioblastoma," Nature Communications, Nature, vol. 16(1), pages 1-23, December.
    20. Upasana Sahu & Matthew P. Mullarkey & Sara A. Murphy & Joshua C. Anderson & Vasanta Putluri & Abu Hena Mostafa Kamal & Jun Hyoung Park & Tae Jin Lee & Alexander L. Ling & Benny A. Kaipparettu & Ashok , 2025. "IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity," Nature Communications, Nature, vol. 16(1), pages 1-21, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-56482-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.